AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 132330 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose therapy with phenytoin (5 to 9 mg/kg/day)
Number of subjects: 13
Study 132330 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose therapy with phenytoin
Number of subjects: 13
Study 31171011 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Process Informed by Data, Evidence and Research (SPIDER)
Number of subjects: 7
Study 31171011 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7
Study 29261676 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritarian mothers
Number of subjects: 487
Study 29261676 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritarian partners
Number of subjects: 487
Study 29261676 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive mothers
Number of subjects: 487
Study 29261676 — intervention group
Group type: EXPERIMENTAL
Intervention: Active families (rated by partners)
Number of subjects: 487
Study 29261676 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who watched television
Number of subjects: 487
Study 29261676 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall television viewing
Number of subjects: 487
Study 26262828 — intervention group
Group type: EXPERIMENTAL
Intervention: Xtampza ER (extended-release oxycodone)
Number of subjects: 740
Study 26262828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study 23836093 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-support intervention
Number of subjects: 33
Study 21616657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric bupivacaine
Number of subjects: 70
Study 19711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative vinorelbine and cisplatin (BR.10)
Number of subjects: 1987
Study 19711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (BR.18)
Number of subjects: 1987
Study 19711465 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (BR.21)
Number of subjects: 1987
Study 19711465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BR.21)
Number of subjects: 1987
Study 22828707 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator assessment of TIMI flow
Number of subjects: 3345
Study 22828707 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator assessment of MBG
Number of subjects: 3345
Study 22828707 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator assessment of final TIMI flow
Number of subjects: 3345
Study 22828707 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator assessment of final MBG
Number of subjects: 3345
Study 22828707 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI 3 flow and MBG 2 to 3
Number of subjects: 3345
Study 22828707 — intervention group
Group type: COMPARATOR
Intervention: Discordant groups of Op and ACL assessments
Number of subjects: 3345
Study 15994258 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (creatine monohydrate 5.7 g, glucose 35 g)
Number of subjects: 38
Study 15994258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose polymer 40.7 g)
Number of subjects: 38
Study 12586855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) injections
Number of subjects: 0
Study 12586855 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and Placebo (RT+P)
Number of subjects: 0
Study 12586855 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injections of testosterone (T; 100 mg/wk)
Number of subjects: 0
Study 12586855 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and Testosterone (RT+T)
Number of subjects: 0
Study 12586855 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 12586855 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals not on Testosterone
Number of subjects: 0
Study 10227334 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg BID)
Number of subjects: 443
Study 10227334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 7777307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lens with topical nonsteroidal anti-inflammatory drug (0.5% ketorolac tromethamine)
Number of subjects: 47
Study 7777307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lens
Number of subjects: 47
Study 7777307 — intervention group
Group type: COMPARATOR
Intervention: Pressure patching
Number of subjects: 47
Study 2108883 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot
Number of subjects: 43
Study 7006069 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (50 mg bid)
Number of subjects: 24
Study 7006069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg tid)
Number of subjects: 24
Study 7006069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-blind period)
Number of subjects: 24
Study 30481942 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk rating model based on non-genetic factors using decision trees
Number of subjects: 783
Study 30481942 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-cancer cases)
Number of subjects: 783
Study 27782922 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week seated yoga program
Number of subjects: 0
Study 27782922 — intervention group
Group type: COMPARATOR
Intervention: Group setting for yoga
Number of subjects: 0
Study 23657754 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Specialists (PSs) added to intensive case management teams for 1 year
Number of subjects: 282
Study 23657754 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (no Peer Specialists)
Number of subjects: 282
Study 23963145 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (4 courses of intravenous carboplatin on day 1 and oral vinorelbin on days 1 and 8 with 3-week intervals, plus radiotherapy 42 Gy/15 starting at the second chemotherapy course)
Number of subjects: 191
Study 23963145 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (4 courses of intravenous carboplatin on day 1 and oral vinorelbin on days 1 and 8 with 3-week intervals)
Number of subjects: 191
Study 21936885 — intervention group
Group type: COMPARATOR
Intervention: SP (sulphadoxine‐pyrimethamine)
Number of subjects: 109
Study 21936885 — intervention group
Group type: COMPARATOR
Intervention: SP+AQ (sulphadoxine‐pyrimethamine + amodiaquine)
Number of subjects: 109
Study 21936885 — intervention group
Group type: COMPARATOR
Intervention: SP+AS (sulphadoxine‐pyrimethamine + artesunate)
Number of subjects: 109
Study 21936885 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 109
Study 21936885 — intervention group
Group type: COMPARATOR
Intervention: SP+AQ
Number of subjects: 109
Study 21936885 — intervention group
Group type: COMPARATOR
Intervention: SP+AS
Number of subjects: 109
Study 18245761 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored geriatric treatment
Number of subjects: 174
Study 18245761 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 16785188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg b.i.d.)
Number of subjects: 12
Study 16785188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16785188 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (placebo)
Number of subjects: 12
Study 12865879 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasogen's immune modulation therapy (IMT)
Number of subjects: 18
Study 12865879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study 11053475 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study 11053475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang II infusion (5 ng Ang II/kg per min)
Number of subjects: 9
Study 11053475 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan premedication plus Ang II infusion (5 ng Ang II/kg per min)
Number of subjects: 9
Study 8865704 — intervention group
Group type: EXPERIMENTAL
Intervention: 25g glucose infusion in 30 minutes (group 1)
Number of subjects: 20
Study 8865704 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g glucose infusion in 30 minutes (group 2)
Number of subjects: 20
Study 8865704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (25g and 50g glucose infusion)
Number of subjects: 20
Study 1353028 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502
Number of subjects: 24
Study 1353028 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 24
Study 6338091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) light treatment
Number of subjects: 18
Study 6338091 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study 30074217 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with low-frequency repetitive transcranial magnetic stimulation (rTMS), 3 days per week for 4 weeks
Number of subjects: 78
Study 30074217 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture cooperated with sham rTMS treatment, 3 days per week for 4 weeks
Number of subjects: 78
Study 26840902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac NS 31.5 mg
Number of subjects: 72
Study 26840902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 20 mg
Number of subjects: 72
Study 26840902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24411080 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 119
Study 24411080 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection (RES)
Number of subjects: 119
Study 21969420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus standard treatment
Number of subjects: 60
Study 21969420 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 60
Study 20033176 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 300 mgI/ml
Number of subjects: 8931
Study 20033176 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 300 mgI/ml
Number of subjects: 8931
Study 20033176 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol 300 mgI/ml
Number of subjects: 8931
Study 20033176 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mgI/ml
Number of subjects: 8931
Study 20033176 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol 320 mgI/ml
Number of subjects: 8931
Study 20033176 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients aged 60 years or over)
Number of subjects: 8931
Study 20033176 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with past history of adverse reactions)
Number of subjects: 8931
Study 20033176 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients receiving contrast media previously)
Number of subjects: 8931
Study 20033176 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients aged 59 years or less)
Number of subjects: 8931
Study 20033176 — intervention group
Group type: COMPARATOR
Intervention: Control group (first period of administration)
Number of subjects: 8931
Study 20033176 — intervention group
Group type: COMPARATOR
Intervention: Control group (late period of administration)
Number of subjects: 8931
Study 20033176 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients receiving contrast media for the first time)
Number of subjects: 8931
Study 18709675 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa administration after overnight withdrawal of dopaminergic medications.
Number of subjects: 50
Study 18709675 — intervention group
Group type: COMPARATOR
Intervention: Cold water immersion test for PD patients 'off'-medication.
Number of subjects: 50
Study 18709675 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pain sensitivity change scores between fluctuators and stable responders/dyskinetic groups.
Number of subjects: 50
Study 15952055 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-based chemotherapy
Number of subjects: 579
Study 12575964 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study 12575964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study 12037652 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) from extra virgin olive oil
Number of subjects: 14
Study 12037652 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat (SFA) from cream
Number of subjects: 14
Study 10194172 — intervention group
Group type: EXPERIMENTAL
Intervention: APRV with spontaneous breathing
Number of subjects: 24
Study 10194172 — intervention group
Group type: COMPARATOR
Intervention: APRV without spontaneous breathing
Number of subjects: 24
Study 10194172 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 24
Study 7785016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannulae
Number of subjects: 99
Study 7785016 — intervention group
Group type: COMPARATOR
Intervention: Venturi face masks
Number of subjects: 99
Study 2211266 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (3 cycles of 120 hr 5-FU infusion 1 g/m2/day plus Cis platin 100 mg/m2 on day 1 of each cycle)
Number of subjects: 75
Study 2211266 — intervention group
Group type: COMPARATOR
Intervention: Definitive local treatment (surgery and post-operative radiation or radiation alone)
Number of subjects: 75
Study 7407477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked lentils (50 g carbohydrate portion)
Number of subjects: 0
Study 7407477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked soya beans (50 g carbohydrate portion)
Number of subjects: 0
Study 7407477 — intervention group
Group type: COMPARATOR
Intervention: Wholemeal bread (control)
Number of subjects: 0
Study 31742460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile multimedia message service (MMS) messages communicating the risks of hookah tobacco use
Number of subjects: 156
Study 27642658 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect in personal events (Study 1)
Number of subjects: 24
Study 27642658 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect in interpersonal events (Study 2)
Number of subjects: 24
Study 27642658 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect in fictional characters (Studies 3 and 4)
Number of subjects: 24
Study 27642658 — intervention group
Group type: EXPERIMENTAL
Intervention: Personification of emotions (Study 5)
Number of subjects: 24
Study 25837980 — intervention group
Group type: EXPERIMENTAL
Intervention: SEC-coated group (n = 20)
Number of subjects: 40
Study 25837980 — intervention group
Group type: COMPARATOR
Intervention: PMEA-coated group (n = 20)
Number of subjects: 40
Study 23735726 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted self-management (CASM)
Number of subjects: 392
Study 23735726 — intervention group
Group type: EXPERIMENTAL
Intervention: CASM plus DD-specific problem solving (CAPS)
Number of subjects: 392
Study 23735726 — intervention group
Group type: COMPARATOR
Intervention: Computer-administered minimal supportive intervention
Number of subjects: 392
Study 21439397 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg/kg, two doses intramuscularly)
Number of subjects: 68
Study 20374316 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg four times per day for 12 weeks)
Number of subjects: 108
Study 20374316 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosage and schedule as erythromycin)
Number of subjects: 108
Study 17600085 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg over 30 min, 16 h and 1 h before chemotherapy)
Number of subjects: 8
Study 17600085 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone administration (control)
Number of subjects: 8
Study 15140663 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of sodium phosphate solution
Number of subjects: 299
Study 15140663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate solution (both single and two doses)
Number of subjects: 299
Study 15140663 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol solution
Number of subjects: 299
Study 11920277 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 400
Study 11920277 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 400
Study 10169390 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b
Number of subjects: 583
Study 10169390 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and prednisone
Number of subjects: 583
Study 7930984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell trait
Number of subjects: 28
Study 7930984 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28
Study 3385217 — intervention group
Group type: EXPERIMENTAL
Intervention: C18:0 PAF
Number of subjects: 0
Study 3385217 — intervention group
Group type: EXPERIMENTAL
Intervention: C16:0 and C18:0 PAFs (1:9 ratio)
Number of subjects: 0
Study 3385217 — intervention group
Group type: EXPERIMENTAL
Intervention: C16:0 and C18:0 PAFs (dose-dependent intradermal injection)
Number of subjects: 0
Study 3385217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of C16:0 and C18:0 PAFs (3:1 or 1:9 ratio)
Number of subjects: 0
Study 31066013 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/day
Number of subjects: 172
Study 31066013 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 100-200 mg/day (intravenous or oral)
Number of subjects: 172
Study 31066013 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin and Fluconazole
Number of subjects: 172
Study 29898701 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk information and web‐based lifestyle advice
Number of subjects: 716
Study 27623967 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-calorie-ketogenic diet (n=22)
Number of subjects: 45
Study 27623967 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet (n=23)
Number of subjects: 45
Study 23828452 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-1000 ml oral rehydration solution
Number of subjects: 60
Study 22177742 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet delivered CBT (iCBT) program (Brighten Your Mood Program)
Number of subjects: 55
Study 22177742 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 55
Study 20335146 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 12 months (n=40)
Number of subjects: 79
Study 20335146 — intervention group
Group type: COMPARATOR
Intervention: No rosuvastatin treatment (n=39)
Number of subjects: 79
Study 18710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tracheal tubes (Group P)
Number of subjects: 40
Study 18710018 — intervention group
Group type: COMPARATOR
Intervention: Wire-reinforced tracheal tubes (Group S)
Number of subjects: 40
Study 18710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group P and Group S)
Number of subjects: 40
Study 15625368 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (HD IL-2)
Number of subjects: 192
Study 15625368 — intervention group
Group type: COMPARATOR
Intervention: IL-2 (5 MIU/m2 subcutaneously every 8 hours for three doses on day 1, then daily 5 days/week for 4 weeks) and interferon (5 MIU/m2 subcutaneously three times per week for 4 weeks)
Number of subjects: 192
Study 15625368 — intervention group
Group type: COMPARATOR
Intervention: IL-2 and IFN
Number of subjects: 192
Study 15251318 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antilymphoblast globulin (ALG) at 10 mg/kg on alternate days (max 6 doses) with low-dose CsA at 8 mg/kg per day and prednisone at 0.25 mg/kg per day
Number of subjects: 100
Study 15251318 — intervention group
Group type: COMPARATOR
Intervention: CsA at 15 mg/kg per day and prednisone at 0.5 mg/kg per day
Number of subjects: 100
Study 10850052 — intervention group
Group type: EXPERIMENTAL
Intervention: Management guidelines for mild and severe pancreatitis
Number of subjects: 0
Study 10850052 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of pseudocysts
Number of subjects: 0
Study 8722584 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock
Number of subjects: 29
Study 8722584 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shock
Number of subjects: 29
Study 1406835 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa combined with cyclophosphamide, vincristine, prednisone, and doxorubicin (treatment group)
Number of subjects: 0
Study 1406835 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine, prednisone, and doxorubicin (control group)
Number of subjects: 0
Study 3934948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 10
Study 3934948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 3934948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3312651 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound
Number of subjects: 900
Study 3312651 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 900
Study 3312651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound with Doppler spectral analysis and oculoplethysmography
Number of subjects: 900
Study 3312651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 900
Study 31159816 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality assistance using Microsoft HoloLens
Number of subjects: 10
Study 31159816 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no augmented reality assistance)
Number of subjects: 10
Study 28178972 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic, family or school variables
Number of subjects: 2523
Study 28178972 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived parental physical activity level
Number of subjects: 2523
Study 28178972 — intervention group
Group type: EXPERIMENTAL
Intervention: Privileged and less privileged socioeconomic status
Number of subjects: 2523
Study 28178972 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity score
Number of subjects: 2523
Study 25185831 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM+yoga
Number of subjects: 184
Study 25185831 — intervention group
Group type: COMPARATOR
Intervention: LSM
Number of subjects: 184